The development of neutralising antibodies, or inhibitors, against infused exogenous factor VIII (FVIII) represents a challenging complication in the treatment of haemophilia A. In persons with nonsevere haemophilia A (NSHA), inhibitor development is thought to be uncommon [1]. Here, F8 is linked to hemophilia A.